More Company News

Hutchison China MediTech

Surufatinib Phase III data in NETs at ESMO 2020 and Publication in The Lancet Oncology
20 Sep 2020Read More

Hutchison China MediTech

Acceptance of second China NDA for surufatinib in pNET
17 Sep 2020Read More

Hutchison China MediTech

Initiation of global fruquintinib FRESCO-2 Phase III in mCRC
04 Sep 2020Read More

Hutchison China MediTech

Initiation of HMPL-453 China Phase II in advanced intrahepatic cholangiocarcinoma
03 Sep 2020Read More

Hutchison China MediTech

Clinical data to be presented at the upcoming ESMO Virtual Congress 2020
24 Aug 2020Read More

Hutchison China MediTech

Plans to submit surufatinib MAA following EMA CHMP scientific advice
10 Aug 2020Read More

Hutchison China MediTech

H120 interims and clinical update
30 Jul 2020Read More

Hutchison China MediTech

Chi-Med and Eli Lilly to collaborate in commercializing Elunate in China
28 Jul 2020Read More

Hutchison China MediTech

China NDA for savolitinib in NSCLC granted Priority Review
28 Jul 2020Read More

Hutchison China MediTech

Initiation of China Phase I trial of IDH1/2 dual inhibitor in haematological malignancies
24 Jul 2020Read More

1 2 3 4 … 7
Return to Hutchison China MediTech
© 2019-20 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).